An Observational Study to Investigate the Feasibility and Patient/Caregiver/Investigator Satisfaction of Video-assisted Telenursing Use in Nurse Support Programs With LCIG
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Enrollment
- 41
- Locations
- 13
- Primary Endpoint
- Participant Acceptance of the AbbVie Duodopa Specialist (ADS) Nurse Support and Communication Access
Study Overview
Brief Summary
Parkinson's disease (PD) is a neurological condition, which affects the brain. PD gets worse over time, but how quickly it progresses varies a lot from person to person. Some symptoms of PD are tremors, stiffness, and slowness of movement. The purpose of this study is to see how feasible and how satisfied participants/caregivers/investigators are with video-assisted telenursing use in nurse support programs with LCIG.
LCIG is an approved drug to treat PD. Approximately 50 adult participants with advanced PD will be enrolled in the study at approximately 10 sites across the world.
The study has 2 groups. In one group, around 25 participants will receive nurse support using video devices. In the second group, around 25 participants will receive nurse support without using video devices. All participants will attend a baseline visit and follow up visits at Week 4 and Week 12. The planned observation period will be 12 weeks.
Participants who are prescribed LCIG by their physicians will have three study related visits. Participants, caregivers, and investigators will be asked to complete questionnaires for the study.
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Prospective
Eligibility Criteria
- Ages
- 18 Years to 85 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Eligible for Levodopa-Carbidopa Intestinal Gel (LCIG) therapy in accordance with the approved local LCIG label in the participating country
- •Formerly LCIG-naive participants who have completed an in-hospital titration, have a Percutaneous Endoscopic transGastric Jejunostomy (PEG-J) placed and are discharged from hospital
- •Decision to treat with LCIG made by the investigator prior to any decision to approach the participant to participate in this study
- •Owns a telecommunication device equipped for videoconferencing (smart phone, tablet, laptop)
- •Willing and able (based on investigator's judgment) to handle the video functionality of the device
- •Caregiver willing to provide written informed consent
Exclusion Criteria
- •Any condition included in the contraindications section of the approved local LCIG label in the participating country
- •Lack of caregiver support
- •Participation in a concurrent interventional clinical trial
- •Lack of motivation or insufficient language skills to complete the study questionnaires
Outcomes
Primary Outcomes
Participant Acceptance of the AbbVie Duodopa Specialist (ADS) Nurse Support and Communication Access
Time Frame: At Week 12
Participant acceptance is measured by the participant satisfaction with the AbbVie Duodopa Specialist (ADS) nurse support and communication access (Visual Analog Sore from 1 to 10).
Secondary Outcomes
- Participant Satisfaction With Video Functionality of the Device(Through Week 12)
- Caregiver Acceptance of ADS Nurse Support and Communication Access(Through Week 12)
- Change of Caregiver Burden(Baseline (Week 0) to Week 12)
- Participant Satisfaction With ADS Nurse Support and Communication Access(Through Week 12)
- Participant Satisfaction with the ADS Nurse Support and Communication Access(At Week 12)
- Caregiver Satisfaction With ADS Nurse Support and Communication Access(Baseline (Week 0) to Week 12)
- Investigator Satisfaction With Nurse Support(At Week 12)